Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2022.63.53 6
Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
Marko Lucijanić
; Hematology Department, Dubrava University Hospital, Zagreb, Croatia
*
Nikolina Bušić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Petra Bistrović
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Ivan Papić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Marina Zelenika Margeta
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Paško Babić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Mihaela Barčan
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Antica Pasarić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Mirna Mustapić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Nevenka Piskač Živković
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Maja Ortner Hadžiabdić
; Centre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
Tomo Lucijanić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Ivica Lukšić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
Bruno Baršić
; Primary Respiratory and Intensive Care Center, Dubrava University Hospital, Zagreb, Croatia
* Dopisni autor.
Sažetak
Aim To evaluate the association of remdesivir use and the
survival of hospitalized patients with coronavirus disease
2019 (COVID-19).
Methods We retrospectively reviewed the medical re
-
cords of 5959 COVID-19 patients admitted to our tertiarylevel hospital from March 2020 to June 2021. A total of 876
remdesivir-treated patients were matched with 876 con
-
trol patients in terms of age, sex, Charlson comorbidity in
-
dex (CCI), WHO-defined COVID-19 severity on admission,
and oxygen requirement at the time of remdesivir use.
Results Among 1752 COVID-19 patients (median age 66
years, 61.8% men), 1405 (80.2%) had severe and 311 (17.8%)
had critically severe COVID-19 on admission. Remdesivir
was given at a median of one day after hospital admission
and at a median of eight days from the onset of symptoms.
Overall, 645 (73.6%) patients received remdesivir before
high-flow oxygen therapy (HFOT) or mechanical ventila
-
tion (MV), 198 (22.6%) after HFOT institution, and 83 (9.5%)
after MV institution. Remdesivir use was associated with
improved survival in the entire cohort (hazard ratio 0.79, P=0.006). Survival benefit was evident among patients receiving remdesivir during low-flow oxygen requirement
(hazard ratio 0.61,
P
<0.001) but not among patients who
received it after starting HFOT (
P
=0.499) or MV (
P
=0.380).
Conclusion Remdesivir, if given during low-flow oxygen
therapy, might be associated with survival benefit in hos
-
pitalized COVID-19 patients
Ključne riječi
Hrčak ID:
331075
URI
Datum izdavanja:
15.12.2022.
Posjeta: 203 *